SILVIA GARTNER TIZZANO Institutions of which they are part Main researcher Genetics Medicine Vall Hebron Institut de Recerca Email SILVIA GARTNER TIZZANO Email Institutions of which they are part Main researcher Genetics Medicine Vall Hebron Institut de Recerca
Research lines Cystic fibrosis. Our paediatric Cystic Fibrosis Unit is one of the most important in Spain regarding number of patients and clinical research. We are the only centre in Spain collaborating in the European Cystic Fibrosis Clinical Trial Network, and in the Cystic Fibrosis Core Network of ERN-Lung. Besides clinical investigation, we are working in translational lab projects in collaboration with the Genetic Medicine group to study the role of the eicosanoid pathway in the lung inflammation of this patients and, more importantly, to personalise the treatments for cystic fibrosis patients through the implementation of primary cultures of epithelial cells (bronchial, nasal) and organoids (rectal epithelium) and the study of transcripts and genomics by next generation sequencing in clinically diagnosed CF patients but with incomplete genomic characterization. IP: Silvia Gartner Tizzano Projects Creixement i Desenvolupament IP: Antonio Moreno Galdó Collaborators: Maria Clemente Leon, Diego Yeste Fernandez, Félix Castillo Salinas, Monica Fernandez Cancio, Inés de Mir Messa, Ariadna Campos Martorell, Sandra Rovira Amigo, Alba Torrent Vernetta, Ana Díez Izquierdo, Noelia Baz Redón, Silvia Gartner Tizzano Funding agency: Agència Gestió Ajuts Universitaris i de Recerca Funding: 0.01 Reference: 2021 SGR 00779 Duration: 01/01/2022 - 30/06/2025 Continued Research Capacity (CRC) IP: Silvia Gartner Tizzano Collaborators: - Funding agency: European Cystic Fibrosis Society Funding: 25500 Reference: ECFS-CTN_CRC2021 Duration: 01/01/2021 - 30/09/2024 ARC-CTN/2017 IP: Silvia Gartner Tizzano Collaborators: - Funding agency: European Cystic Fibrosis Society Funding: 60200 Reference: ECFS-CTN_ARC2017 Duration: 01/01/2017 - 30/09/2020 Estudios funcionales de mutaciones del gen CFTR para establecer una terapia personalizada en pacientes con Fibrosis Quística IP: Eduardo Fidel Tizzano Collaborators: Paula Fernández Álvarez, Silvia Gartner Tizzano Funding agency: Fundación Invest. Médica Mutua Madrileña Funding: 104213 Reference: MM/XIV/RECERCA/2017/TIZZANO Duration: 10/10/2017 - 30/09/2021 Pagination Current page 1 Page 2 Next page › Last page »
